- Product
- Oral treatment by Sanofi has the highest number of defects
- by Kim JiEun Dec 26, 2019 06:30am
- Ten defects were found in the same product of the same company a year The Seoul Pharmaceutical Society (Chairman Dong-ju Han), the pharmacy committee (Vice chairman Yong-seok Choi, Head Commissioner Woo-young Chang, Soo-hyun Byun, and Tae-seok Kang), and the Pharmacist Guidance Committee (Chairman Kyung-Jin Jeon and Soo-Yul Lim) announced
- Product
- “Lipitor not sold out”, Pfizer clarifies rumors
- by Kim JiEun Dec 18, 2019 06:24am
- Rumors of cholesterol lowering treatment Lipitor tablet going out of stock have been spreading throughout major pharmacies, but its company clarified the rumor is false. Pfizer Upjohn Korea on Tuesday told Daily Pharm that the manufacturing of Lipitor 10 mg tablet (28BLP/ 90BLT) has no issue at the moment. The company’s statement w
- Product
- Stock-out Cytotec and Livalo V supply to resume from January
- by Kim, Min-Gun Dec 12, 2019 10:52pm
- Some doses of Pfizer Korea’s stomach ulcer preventing drug Cytotec (misoprostol) has run out of stock and the company say the supply would resume around early next year. Sources from the pharmaceutical industry reported on Dec. 11 that there is a temporary shortage on 200 mcg 120 BTL dose of Cytotec. Pin pointing at the delay in manu
- Product
- Metformin impurity amount, theoretically 1/90 of Ranitidine
- by Kim, Jin-Gu Dec 10, 2019 06:31am
- With Metformin, issues of impurity detection have been raised, and it is possible that N-nitrosodimethylamine (NDMA) will be detected much less than earlier Ranitidine or Nizatidine. According to officials at the MFDS on Dec 9, a qualitative structure activity relationship (QSAR) is used as a simple test to determine the toxicity of a su
- Product
- Just over a year since Tamiflu fears after suicide in Busan
- by Jung, Heung-Jun Nov 20, 2019 11:50pm
- Consultation about hallucinations is burden, but can be explained in writing. Tamiflu prescription patients are expected to gradually increase as the flu season approaches this year. Last year, there was a need to consult side effect of hallucinations after the fall of a middle school girl who took Tamiflu in Busan. At the time, The is
- Product
- The Minister Lee, Enhanced post-de-factor management
- by Jung, Heung-Jun Nov 18, 2019 10:21pm
- Lee Eui-kyung, the Minister of MFDS has released a long-term follow-up plan to strengthen the post-de-factor safety management system. On the 15th, the Minister Lee attended Korean Academy of Social & Managed Care Pharmacy and presented the four directions of drug safety management in four categories: patient safety, accessibility, safety
- Product
- 7 out of 10 doctors exposed to patient violence
- by Kang, Shin-Kook Nov 15, 2019 06:29am
- Apparently, seven out of ten doctors have faced verbal abuse or physical violence against them by a patient or their family. On Nov. 13, Korean Medical Association (KMA, President Choi Dae-zip) published a result of an urgent survey conducted on 2,034 member doctors of the organization. The survey result found among 1,455 doctors (71.5 p
- Product
- Vibramycin restocking delayed again, but for how long?
- by Kim, Min-Gun Nov 10, 2019 09:58pm
- Restocking of Pifzer Korea’s antibiotic Vibramycin-N (doxycycline) 100mg (500T), initially scheduled in November, has been delayed again. Since July last year, this is an eighth supply delay notice. Number of pharmacies is to experience inconvenience due to the delay. On November 5, Pfizer Korea notified all drug distribution companie
- Product
- Lixiana joins NOAC market race late but takes the lead
- by Byun Kyung A Oct 31, 2019 09:59am
- A follow-on drug in the non-vitamin K antagonist oral anticoagulant (NOAC) market, Lixiana, continues to lead the market. The treatment took the lead from Xarelto in last January for the first time, and it has been the most prescribed drug in the market for nine consecutive months. Pfizer and Bristol-Myers Squibb’s Eliquis had to face a Ko
- Product
- Maviret takes up 83% of HCV treatment market share
- by Byun Kyung A Oct 31, 2019 09:41am
- Abbvie broke through the hepatitis C virus (HCV) treatment market and dominated 83 percent of oral outpatient prescription market only with its pan-genotype HCV treatment, Maviret, launched last year. Gilead once dominated the market with two items, but their prescription ratio shriveled down to 12 percent. On Oct. 30, a pharmaceutic
